Effects of regular, glulisine, and aspart insulin on vascular endothelial growth factor and angiotensinogen expression in hyperglycemic retinal pigment epithelial (RPE) and human retinal endothelial cells (HRECs)., PMID:40510890
Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes., PMID:40501244
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study., PMID:40445776
Long-acting glucose-responsive insulin with swift onset-of-action., PMID:40348134
Subcutaneous Insulin Aspart Every 4 Hours in the Treatment of COVID-19 Patients With Mild-to-Moderate Diabetic Ketoacidosis: A Case Series., PMID:40309296
Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study., PMID:40258224
X-ray crystallographic and hydrogen deuterium exchange studies confirm alternate kinetic models for homolog insulin monomers., PMID:40257998
Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study., PMID:40236299
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability., PMID:40211481
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458
EXPRESS: Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus., PMID:40176332
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial., PMID:40129237
Prescription patterns and the cost of antihyperglycemic drugs in patients with diabetes mellitus in Iran from 2014 to 2019., PMID:40096947
Premixed insulin: Advantages, disadvantages, and future., PMID:40093285
Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring-Derived Glycemic Metrics in Hospitalized Inpatients., PMID:40067436
Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus., PMID:40049655
What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives., PMID:40013436
A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials., PMID:39996365
Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers., PMID:39982761
Impact of setting distinct target blood glucose levels on endogenous insulin suppression and pharmacodynamics of insulin preparations., PMID:39959272
Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information., PMID:39951116
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers., PMID:39930729
First Dimension Trap-and-Elute Combined with Second Dimension Reversed-Phase Liquid Chromatography Separation Using a Two-Dimensional-Liquid Chromatography-Tandem Mass Spectrometry System for Sensitive Quantification of Human Insulin and Six Insulin Analogs in Plasma: Improved Chromatographic Resolution and Stability Testing., PMID:39930590
BioJect: An in vitro platform to explore release dynamics of peptides in subcutaneous drug delivery., PMID:39923852
Pharmacotherapy of type 1 diabetes - part 1: yesterday., PMID:39875200
Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery., PMID:39868600
Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unit., PMID:39863397
Autoimmune Polyglandular Syndrome Type 3: A Case Report., PMID:39834989
Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study., PMID:39817213
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart., PMID:39815718
Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice., PMID:39806553
Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes., PMID:39786791
Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis., PMID:39763007
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China., PMID:39703112
Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study., PMID:39691304
Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes., PMID:39665530
Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes., PMID:39643003
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II., PMID:39629799
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study., PMID:39620193
A Case of Exogenous Insulin Autoimmune Syndrome: A Case Report., PMID:39575003
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial., PMID:39546502
Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors., PMID:39533598
Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart-A secondary analysis of the CopenFast trial., PMID:39497517
Analysis of multi-disulfide bridges for insulin aspart by stepwise reduction and differentiated alkylation., PMID:39472333
Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study., PMID:39464932
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing., PMID:39460908
Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database., PMID:39457586